Leidos to Participate in the J.P. Morgan 2024 Industrials Conference
Leidos to Participate in the J.P. Morgan 2024 Industrials Conference
PR Newswire
RESTON, Va., March 5, 2024
Live Audio Webcast Available on March 12, 2024, from 10:45 a.m. to 11:20 a.m. ET
RESTON, Va., March 5, 2024 /PRNewswire/ -- Leidos (NYSE: LDOS), a FORTUNE 500® innovation company, will participate in the J.P. Morgan 2024 Industrials Conference being held in New York City.
Chris Cage, Chief Financial Officer, will engage in a question and answer "fireside chat" on Tuesday, March 12, 2024, at 10:45 a.m. ET.
A live audio webcast of the event will be available on the Leidos Investor Relations website at http://ir.leidos.com. A replay of the webcast will be available following the presentation at the same link listed above for 30 days afterward.
About LeidosLeidos is a Fortune 500® innovation company rapidly addressing the world's most vexing challenges in national security and health. The company's global workforce of 47,000 collaborates to create smarter technology solutions for customers in heavily regulated industries. Headquartered in Reston, Virginia, Leidos reported annual revenues of approximately $15.4 billion for the fiscal year ended December 29, 2023. For more information, visit www.leidos.com.
CONTACTS: | |
Media contact: | Investor Relations: |
Melissa Lee Dueñas | Stuart Davis |
571.526.6850 | 571.526.6124 |
ir@leidos.com |
View original content:https://www.prnewswire.com/news-releases/leidos-to-participate-in-the-jp-morgan-2024-industrials-conference-302078860.html
SOURCE Leidos
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise